Sunday, 22 November 2026
Rīga TV

World and Latvian news in one place

HealthPublished: 22 November 2026 at 16:04

Costly gene test for breast cancer patients still paid by donations as state delays funding

In Latvia, breast cancer patients still have to pay for a test showing whether they need chemotherapy. The Ministry of Health had promised to add it to the state-funded services list this year, but this has not happened.

Foto: LSM (rus)

In Latvia, around 1,200 women are diagnosed with breast cancer each year. One stage of treatment is chemotherapy, which is often the hardest to endure. Gene activity tests can show whether chemotherapy is needed at all after surgery, sparing some patients from it. The test costs 3,000 euros. The Ministry of Health had promised to include it in the list of state-funded services this year, but that has not happened, so patients will most likely have to keep finding the money themselves, according to the Latvian Radio programme "Atvērtie faili".

An artist's experience

Artist Ieva Liepiņa received an invitation to the national breast cancer screening programme earlier this year, and a mammogram revealed a tumour. She had surgery at the start of July. Doctors warned her that tissue samples would be checked with the Oncotype DX test, which shows whether chemotherapy would be of any use. After the operation she was told the analysis was now available only for a fee. Her family did not have that sum, so she turned to the donation platform Ziedot.lv and to friends and acquaintances. The money was raised in less than a day. The result showed that chemotherapy would not be effective for her type of tumour. She is now receiving hormone therapy and radiation, which will end in December.

Pilot project results

Professor Alinta Hegmane, director of the Latvian Oncology Centre at Riga East Clinical University Hospital, explains that not every patient needs chemotherapy, so selection is key. The tests were trialled in Latvia in a pilot project funded with European money that began two years ago. In just under a year it included 208 patients. About two-thirds, more than 150 women, could avoid unnecessary chemotherapy. The auditing firm KPMG Baltics also assessed the economic benefit: each euro spent returns roughly 2–3 euros to the state, over a million euros in total. The pilot project ended in spring.

Comments

0/1500

Comments are automatically moderated. No hate, threats, personal data or spam.

Loading comments…

More in this category